Key Takeaways:
- AIM Vaccine is finally landing on the Hong Kong Stock Exchange at its third attempt, but has only issued 0.8% of its total share capital, raising a net HK$70 million
- The company issued equity incentives worth a whopping 900 million yuan to its chairman before going public, and swung from profit to loss last year
